Tag: heart failure
-
The ATTR-CM commercial map — revenue and narrative are decoupled: stabilizers own the market, siRNA becomes a blockbuster, and the real bottlenecks are the add-on outcome threshold and the price-value gap
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All revenue, prescription, pricing and reduction figures are attributed to the company’s own results (press release / SEC), to the ICER report, or to market-analysis reporting. The acoramidis-versus-tafamidis real-world comparison…
-
Hard outcomes in ATTR-CM — mortality and CV events are settled within each trial, but “which modality is better” is undeterminable because there is not a single head-to-head RCT
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. Every hard-outcome figure is attributed to its own trial’s primary paper or press release; the eplontersen miss and monotherapy signal are attributed to the AstraZeneca/Ionis press release of 2026-07-09 (press-release…
-
The ATTR cardiomyopathy landscape — four modalities target one protein, but the siRNA-success/ASO-miss split is cross-trial, not head-to-head
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All reduction and outcome figures are attributed to the sponsoring trial or company; some are company press releases rather than peer-reviewed data (noted inline). The eplontersen result below is a…
-
Does finerenone move hard outcomes, or mainly organ and morbidity endpoints? A close read of FIDELITY, FINEARTS-HF and FINE-HEART
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduced kidney and heart-failure morbidity endpoints consistently across three pooled trial layers. But the single hardest endpoint, cardiovascular death,…
-
Do incretins move hard outcomes in CKM, not just weight? A close read of SELECT, FLOW and SUMMIT
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. GLP-1 / incretin agents lowered hard cardiovascular (SELECT) and kidney (FLOW) outcomes. In SELECT’s pre-specified analysis, roughly two-thirds of the cardiovascular benefit appeared independent of…
Uthando Nethemba 